Analyst: Lundbeck migraine study is "exciting" news
Lundbeck’s preventive migraine candidate, Lu AG09222, met its primary endpoint in a phase II trial, which the Danish pharmaceutical announced on Wednesday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.